Alexion Eyes Soliris' Japan Launch, Analysts Upbeat About Pricing And Market Size
This article was originally published in PharmAsia News
Executive Summary
Japan's Ministry of Health, Labor and Welfare recently approved Alexion Pharmaceutical's Soliris (eculizumab) for the rare blood disorder paroxysmal nocturnal hemoglobinuria, and analysts believe it may beat initial expectations once it hits the market
You may also be interested in...
Alexion Prepares To Launch Soliris In Japan Following Record NHI Price Listing Time
Japan's Central Social Medical Insurance Agency (Chuikyo) approved Soliris (eculizumab) National Health Insurance price listing at its June meeting, three months ahead of a previously estimated fall listing, and Soliris maker Alexion Pharmaceutical is gearing up for an earlier launch in Japan
Alexion Prepares To Launch Soliris In Japan Following Record NHI Price Listing Time
Japan's Central Social Medical Insurance Agency (Chuikyo) approved Soliris (eculizumab) National Health Insurance price listing at its June meeting, three months ahead of a previously estimated fall listing, and Soliris maker Alexion Pharmaceutical is gearing up for an earlier launch in Japan
Japan Adds 12 Drugs To NHI Price List; Takeda Takes Four, Pfizer, Alexion Also Gain
Japan's Central Social Medical Insurance Agency (Chuikyo) June 2 approved the addition of 29 products of 12 ingredients. Among them, six are new chemical entities, four are new combinations and two are new administration routes with one additional indication and dosage